Portfolio

Peptomyc announces the beginning of a Phase 2 clinical trial of OMO-103 in advanced osteosarcoma

January 16, 2025

Peptomyc SL, a clinical-stage biotech company focused on developing new mini-protein therapeutics targeting MYC, the most dysregulated oncogene in human cancer, announced the approval of a Phase 2 trial of OMO-103, the Company’s lead candidate, in pediatric and adult patients with advanced osteosarcoma.

 

Read more